dc.contributor.author | Usmanij, EA | |
dc.contributor.author | Natroshvili, T | |
dc.contributor.author | Timmer-Bonte, JNH | |
dc.contributor.author | Oyen, WJG | |
dc.contributor.author | van der Drift, MA | |
dc.contributor.author | Bussink, J | |
dc.contributor.author | Geus-Oei, L-FD | |
dc.date.accessioned | 2017-03-06T15:33:19Z | |
dc.date.issued | 2017-08 | |
dc.identifier.citation | Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017, 58 (8), pp. 1243 - 1248 | |
dc.identifier.issn | 0161-5505 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/472 | |
dc.identifier.eissn | 1535-5667 | |
dc.identifier.doi | 10.2967/jnumed.116.185314 | |
dc.description.abstract | 18 F-FDG PET/CT is potentially applicable to predict response to chemotherapy in combination with bevacizumab in patients with advanced non-small cell lung cancer (NSCLC). Methods: In 25 patients with advanced nonsquamous NSCLC, 18 F-FDG PET/CT was performed before treatment and after 2 wk, at the end of the second week of first cycle carboplatin-paclitaxel and bevacizumab (CPB) treatment. Patients received up to a total of 4 cycles of CPB treatment. Maintenance treatment with bevacizumab monotherapy was continued until progressive disease without significant treatment-related toxicities of first-line treatment. In the case of progressive disease, bevacizumab was combined with erlotinib. SUV corrected for lean body mass (SUL and SUL peak ) were obtained. PERCIST were used for response evaluation. These semiquantitative parameters were correlated with progression-free survival and overall survival (OS). Results: Metabolic response, defined by a significant reduction in SUL peak of 30% or more after 2 wk of CPB, was predictive of progression-free survival and OS. For partial metabolic responders ( n = 19), the median OS was 22.8 mo. One-year and 2-y OS were 79% and 47%, respectively. Nonmetabolic responders ( n = 6) (stable metabolic disease or progressive disease) showed a median OS of 4.4 mo (1-y and 2-y OS was 33% and 0%, respectively) ( P < 0.001). Conclusion: 18 F-FDG PET/CT after 1 treatment cycle is predictive of outcome to first-line chemotherapy with bevacizumab in patients with advanced nonsquamous NSCLC. This enables identification of patients at risk of treatment failure, permitting treatment alternatives such as early switch to a different therapy. | |
dc.format | Print-Electronic | |
dc.format.extent | 1243 - 1248 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.subject | Humans | |
dc.subject | Carcinoma, Non-Small-Cell Lung | |
dc.subject | Lung Neoplasms | |
dc.subject | Fluorodeoxyglucose F18 | |
dc.subject | Follow-Up Studies | |
dc.subject | Predictive Value of Tests | |
dc.subject | Time Factors | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Bevacizumab | |
dc.subject | Positron Emission Tomography Computed Tomography | |
dc.title | The Predictive Value of Early In-Treatment <sup>18</sup>F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non-Small Cell Lung Cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-01-31 | |
rioxxterms.versionofrecord | 10.2967/jnumed.116.185314 | |
rioxxterms.licenseref.startdate | 2017-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | |
pubs.issue | 8 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging | |
pubs.publication-status | Published | |
pubs.volume | 58 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Translational Molecular Imaging | en_US |
dc.contributor.icrauthor | Oyen, Willem | en |